B
Bull
Bull · 25%IMMX
$3.24
Precio del escenario
$13.940
-0.361 (-2.59%)Al cierre
Loading chart…
- High
- 14.170
- Open
- 14.060
- VWAP
- 13.96
- Vol
- 1.14M
- Mkt Cap
- 56.26M
- Low
- 13.760
- Amount
- 15.96M
- EV/EBITDA, TTM
- 0.00
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
AI analysis of Immix Biopharma Inc (IMMX)
buyImmix Biopharma Inc is a good buy right now, trading at $13.94 with a strong analyst price target of $27 from Bank of America, suggesting a potential upside of about 93%. Additionally, the stock has shown impressive performance with a year-to-date change of +156.72% and a 1-year change of +511.40%. The main risk is the negative net income, which has been consistently high, with the latest quarter reporting a net loss of $11,557,002.
Métricas de valoración
The current forward P/E ratio for Immix Biopharma Inc (IMMX) is 0.00, compared to its 5-year average forward P/E of -3.84.
Alphio AI Price Scenarios for IMMX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding IMMX
Cronología de eventos
Noticias
7.008-13PRnewswirePomerantz LLP Investigates Securities Fraud Claims Against Immix Biopharma
7.008-07PRnewswirePomerantz LLP Investigates Securities Fraud Claims Against Immix Biopharma
7.008-07NewsfilterSBS Investigates Claims for Immix Biopharma Investors
- 8.508-04Newsfilter
ImmixBio to Host Investor Meetings at Morgan Stanley Healthcare Conference
7.007-21GlobenewswireImmix Biopharma Under Investigation for Securities Fraud
IMMX FAQ — answered by Alphio AI
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Immix Biopharma Inc is a good buy right now, trading at $13.94 with a strong analyst price target of $27 from Bank of America, suggesting a potential upside of about 93%. Additionally, the stock has shown impressive performance with a year-to-date change of +156.72% and a 1-year change of +511.40%. The main risk is the negative net income, which has been consistently high, with the latest quarter reporting a net loss of $11,557,002.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.